# Pediatric Obstructive Sleep Apnea
## Overview
Pediatric obstructive sleep apnea (OSA) affects 1-5% of children and has significant neurocognitive, behavioral, and cardiovascular consequences if untreated. Adenotonsillar hypertrophy is the primary cause in otherwise healthy children, making adenotonsillectomy the first-line treatment. However, persistent OSA after surgery is common, particularly in obese children, and requires further evaluation including drug-induced sleep endoscopy (DISE) and additional interventions.
## Pathophysiology
Upper airway obstruction during sleep due to adenotonsillar hypertrophy, craniofacial anatomy, obesity, and neuromuscular tone. Loss of pharyngeal dilator muscle tone during sleep (genioglossus, tensor veli palatini). Adenotonsillar hypertrophy: relative to airway size (even moderate hypertrophy is significant in a small airway). Obesity: fat deposition in parapharyngeal and tongue base tissues. Craniofacial factors: midface hypoplasia (Down syndrome), retrognathia (Pierre Robin sequence), narrow palate.
## Consequences of Untreated Pediatric OSA
**Neurocognitive**: poor school performance, attention deficits (may mimic ADHD), behavioral problems, executive function impairment. **Cardiovascular**: pulmonary hypertension, cor pulmonale, right ventricular dysfunction, systemic hypertension. **Growth**: failure to thrive (increased metabolic demand, growth hormone suppression). **Quality of life**: daytime sleepiness, enuresis, morning headaches.
## Diagnosis
### Clinical Assessment
History: snoring (habitual snoring in >80% of OSA), witnessed apneas, restless sleep, mouth breathing, enuresis, daytime sleepiness, behavioral issues. Physical exam: tonsillar size (Brodsky scale), adenoid facies (long face, open mouth, high-arched palate), obesity (BMI percentile), craniofacial anomalies. Modified Epworth Sleepiness Scale (pediatric version).
### Polysomnography (PSG)
Gold standard for diagnosis.
| Severity | AHI (events/hour) |
|----------|-------------------|
| Normal | <1 |
| Mild OSA | 1-5 |
| Moderate OSA | 5-10 |
| Severe OSA | >10 | Additional parameters: SpO2 nadir, end-tidal CO2 (hypoventilation), sleep architecture, arousal index. Indications for preoperative PSG: Age <2 years. Obesity. Down syndrome. Craniofacial anomalies. Neuromuscular disorders. Discordance between symptoms and physical findings. Severe comorbidities. |
### Home Sleep Testing
Not validated in pediatric populations as well as adult, May underestimate severity. Not recommended as standard of care for pediatric OSA diagnosis.
## Treatment
### Adenotonsillectomy (First-Line)
Curative in 75-85% of otherwise healthy, non-obese children. Complete resolution rate lower in obese children (~50%) and syndromic populations. Postoperative PSG recommended for high-risk children and those with residual symptoms. CHAT study (Childhood Adenotonsillectomy Trial): demonstrated improvements in behavior, quality of life, and PSG parameters compared to watchful waiting; no significant difference in standardized attention or executive function scores.
### Persistent OSA After Adenotonsillectomy
Defined as AHI >= 1 on postoperative PSG. Risk factors: obesity, age >7, severe preoperative OSA, craniofacial anomalies, Down syndrome. Requires further evaluation and treatment.
### Drug-Induced Sleep Endoscopy (DISE)
Endoscopic evaluation of the upper airway during pharmacologically induced sleep. Identifies the site(s) and pattern of obstruction. Sedation agents: propofol (most common), dexmedetomidine, or combination. VOTE classification: Velum, Oropharyngeal lateral walls, Tongue base, Epiglottis. Each site graded: no obstruction, partial, or complete. Pattern: anteroposterior, lateral, concentric. Guides targeted surgical intervention for persistent OSA.
### Additional Surgical Options for Persistent OSA
**Lingual tonsillectomy**: for tongue base obstruction from lingual tonsillar hypertrophy; coblation or robotic-assisted. **Supraglottoplasty**: if laryngomalacia contributes (common in Down syndrome). **Tongue base reduction**: coblation channeling, midline glossectomy. **Orthodontic expansion**: rapid maxillary expansion (RME) for narrow palate; widens the nasal floor and increases nasal airway. **Mandibular distraction osteogenesis**: for severe retrognathia (Pierre Robin, Treacher Collins). **Hypoglossal nerve stimulation**: under investigation for adolescents with Down syndrome (FDA approved for this population). **Epiglottopexy**: for epiglottic collapse.
### Non-Surgical Management
**CPAP/BiPAP**: for persistent OSA after surgery or non-surgical candidates. Effective but adherence is challenging in children. Requires mask fitting, titration PSG, and close follow-up. **Intranasal corticosteroids**: fluticasone or mometasone; mild OSA or residual adenoid tissue; modest benefit. **Montelukast**: leukotriene receptor antagonist; mild OSA or residual adenoid hypertrophy; limited evidence. **Positional therapy**: for positional-dependent OSA. **Weight management**: essential for obese children with OSA. **Myofunctional therapy**: oropharyngeal exercises to improve muscle tone; emerging evidence.
## Special Populations
### Down Syndrome
OSA prevalence: 50-80%. Multifactorial: midface hypoplasia, macroglossia, hypotonia, lingual tonsil hypertrophy, laryngomalacia, obesity, subglottic stenosis. Adenotonsillectomy alone resolves OSA in only ~50%, Multilevel obstruction common; DISE is particularly useful. Higher perioperative risk: atlantoaxial instability (flexion-extension X-rays), cardiac anomalies. Hypoglossal nerve stimulation (Inspire) approved for adolescents >= 13 with Down syndrome.
### Obesity
Obesity is the strongest risk factor for persistent OSA after adenotonsillectomy. Fat deposition in lateral pharyngeal walls and tongue base, Weight loss significantly improves OSA severity, May require CPAP as adjunct to surgery.
### Craniofacial Anomalies
Pierre Robin sequence: mandibular distraction osteogenesis or tongue-lip adhesion. Treacher Collins: mandibular distraction, tracheotomy for severe cases. Achondroplasia: midface hypoplasia, foramen magnum stenosis; multidisciplinary management.
Drug-induced sleep endoscopy (DISE) findings using the VOTE classification. Four endoscopic panels showing sites of obstruction during pharmacologically induced sleep. Panel A: Velum (palatal) obstruction with anteroposterior collapse of the soft palate against the posterior pharyngeal wall. Panel B: Oropharyngeal lateral wall obstruction with medialization of the lateral pharyngeal walls and tonsillar tissue narrowing the airway. Panel C: Tongue base obstruction with posterior displacement of the tongue base against the posterior pharyngeal wall. Panel D: Epiglottic obstruction with posteroinferior collapse of the epiglottis covering the laryngeal inlet. Each panel is graded (partial vs. complete) and labeled with the direction of collapse (AP, lateral, concentric).
Pediatric OSA management algorithm. Flowchart starting with clinical suspicion of OSA, proceeding to polysomnography. Branches by severity: mild (AHI 1-5) directs to trial of intranasal steroids, montelukast, and weight management; moderate-severe (AHI >5) directs to adenotonsillectomy. Post-operative pathway: reassessment at 6-8 weeks; if persistent symptoms, repeat PSG. If persistent OSA: DISE for site identification, then targeted surgery (lingual tonsillectomy, supraglottoplasty, orthodontic expansion) or CPAP. Special population sidebars for Down syndrome, obesity, and craniofacial anomalies with modified pathways.
Anatomic sites of upper airway obstruction in pediatric OSA. Midsagittal illustration of the pediatric upper airway showing the four levels of potential obstruction: (1) Nasal/nasopharyngeal level with adenoid hypertrophy, (2) Oropharyngeal level with palatine tonsillar hypertrophy and soft palate collapse, (3) Tongue base/hypopharyngeal level with lingual tonsillar hypertrophy and tongue base prolapse, (4) Laryngeal level with epiglottic collapse or laryngomalacia. Each level is color-coded and labeled with the corresponding DISE VOTE category and the surgical interventions targeting that level.
## Clinical Pearls
Adenotonsillectomy is first-line for pediatric OSA but cures only 75-85% of non-obese children; obesity is the strongest predictor of persistent disease. Postoperative PSG should be obtained in high-risk populations (obesity, Down syndrome, severe preoperative OSA, craniofacial anomalies) to confirm resolution. DISE is invaluable for identifying the site of persistent obstruction after adenotonsillectomy; it guides targeted surgical intervention rather than empiric additional surgery. In Down syndrome, OSA is nearly universal and multifactorial; expect multilevel obstruction and plan accordingly; hypoglossal nerve stimulation is an emerging option for adolescents. Children with severe OSA (AHI >10, SpO2 nadir <80%) should be monitored overnight after adenotonsillectomy due to the risk of postoperative respiratory compromise and pulmonary edema. Rapid maxillary expansion is an underutilized treatment that can improve both nasal breathing and OSA in children with narrow palatal arches.
## References
- Marcus CL, Brooks LJ, Draper KA, et al. "Diagnosis and management of childhood obstructive sleep apnea syndrome." *Pediatrics*. 2012;130(3):576-584.
- Marcus CL, Moore RH, Rosen CL, et al. "A randomized trial of adenotonsillectomy for childhood sleep apnea." *N Engl J Med*. 2013;368(25):2366-2376.
- Ishman SL, Tang A, Cohen AP, et al. "Drug-induced sleep endoscopy in children." *Otolaryngol Head Neck Surg*. 2019;161(2):199-207.
- Caloway CL, Diercks GR, Keamy D, et al. "Update on hypoglossal nerve stimulation in children with Down syndrome and obstructive sleep apnea." *Laryngoscope*. 2020;130(4):E263-E267.